Abbott (NYSE:ABT) today announced a significant milestone abroad with the opening of a new manufacturing facility in Ireland.

But now, Abbott’s FreeStyle Libre 2 and 3 have received the first and only FDA clearance that allows patients to keep their ...

Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

iLet Bionic Pancreas The iLet Bionic Pancreas With the FreeStyle Libre 3 Plus Sensor Beta Bionics' flagship product, the iLet Bionic Pancreas, is an autonomous insulin delivery system that ...

Abbott's FreeStyle Libre 2 and 3 continuous glucose monitors no longer need to be removed for imaging tests. CGM readings during an MRI may be affected for up to an hour after the procedure. While ...

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott today officially opened its new diabetes technology manufacturing facility in Kilkenny, Ireland. The site will employ ...

Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, ...

Abbott announces $100,000 grant to The Ireland Funds to support the education of young people from three DEIS schools located in Kilkenny ...

The site is a global manufacturing centre of excellence for Abbott’s diabetes care business and will employ more than 800 ...

The new facility is part of a €440m investment made by Abbott in Ireland. The initial announcement was made back in 2022.